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Senescence As a Mode of Tumor
Suppression
by Ruth Sager*
Two independent lines of experimental evidence are presented in support of the hypothesis that senes-
cence is a normal mechanism of tumor suppression, a homeostatic device designed through evolution to
limit cell proliferation irreversibly and thereby to protect the organism against cancer. One set of exper-
iments uses normal human foreskin fibroblasts, transfected at early passage with SV40 DNA and subse-
quently infected with the K-ras virus. Ifthe cells are immortal prior to infection, they become tumorigenic
and make large tumors in nude mice, whereas ifthey are not immortal, though expressingSV40 T-antigen,
they make tiny tumors that senesce in the test mouse after as many doublings as similar cells make in
culture. This result demonstrates that immortalization is essential for progressive tumor growth in vivo.
The second set of experiments demonstrate that normal human mammary epithelial cells can be im-
mortalized by transfection with viral DNA from human papilloma virus 16 or 18, although these viruses
have not been associated withbreastcancer. Theeffective immortalization andotherpremalignant changes
induced by human papilloma virus transfection are accompanied by chromosome changes that may con-
tribute to the partially transformed phenotypes. None of the cloned or pooled transfectants have been
tumorigenic in the nude mouse assay. Here, too, immortalization is experimentally separable from tumor-
forming ability.
Introduction
Life is a balancing act. Good and evil, right and
wrong, production and destruction are in opposition, at
the social level. And at the biological level, networks of
regulation interact to maintain the metabolic balance
and offset proliferation with differentiation, inflamma-
tionwith anti-inflammatory mechanisms, etc. In aword:
homeostasis. The balance between opposing forces is
part of the underlying biological design, a fundamental
theme in cell and organism.
This theme is particularly evident in the cancer field,
where genes encodingtumor-suppressor proteins are at
least as important in tumor progression as those (i.e.,
oncogenes) with tumor-promoting activity. Losses of
tumor-suppressor activity, as well as the activation of
oncogenes, are driven by genomic instability leading to
mutations, large deletions, rearrangements, and aneu-
ploidy (1).
These progressive genomic changes include effects on
cells that regulate cell proliferation and differentiation,
enmeshing cancer onset and progression with systemic
aging and with cellular senescence and immortalization.
The long, multistage progression of cancer, as well as
the acceleration of cancer incidence with age, both high-
light the existence ofmultiple devices, cellular and sys-
temic, that have evolved to protect us against cancer
(1).
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At the cellular level, three general mechanisms of
tumor suppression have been documented: the stability
of the human genome, the mechanisms of proliferation
control, and the process of terminal differentiation,
which involves the irreversible loss of proliferative ca-
pacity. Senescence is a kind of terminal differentiation
in which cells can no longer respond to any known pro-
liferation stimulus, but do carry on metabolic activities.
Current evidence implicates four dominant genes or
complementation groups in senescence, implying that
loss of these genes or their functions is essential for
immortalization (2).
Blocking Tumor Growth by
Senescence
In my laboratory a few years ago, we carried out
experiments designed to examine directly the role of
senescence in tumor suppression (3). Because of their
relevance to current work, these experiments will be
briefly reviewed here. The initial aim was to convert
normal human diploid fibroblasts into tumor-forming
cells by transfection with specific transforming genes.
We used a plasmid containing SV40 early-region DNA
to try to immortalize the cells, but we found after ex-
tensive studies that the integrated SV40 DNA, while
coding for T-antigen, did not immortalize these cells,
although some transfectants had an extended life span.
The cells appeared morphologically transformed andR. SAGER
were used for the second step, namely, introduction of
viral Kirsten ras.
The nonimmortalized SV40-transfected FS-2 cells,
called FSSV, were compared with a human cell line,
Va2, which had been selected as immortalized but not
tumor-forming after infection with SV40 virus. Since
SV40 virus immortalization ofhuman cells is very rare,
it was presumably the result of additional genetic
changes in Va2 beyond SV40 DNA integration that de-
termined their immortalization. FS-2, FSSV, and Va2
cells were each infected with viral K-ras, which had
been pseudotyped with an endogenous baboon virus to
facilitate entry into human cells (4). The cellpopulations
before and after transfection orinfection were carefully
monitored to count population doublings.
Both the FSK and the FSVK cell populations re-
covered from the infection experiments senesced in cell
culture after a number of doublings similar to those
occurringintheuninfectedcells, whereastheVa2Kcells
remained immortal. When tested in nude mice, the
Va2K cells made large persistent tumors, whereas the
FSVK line, containing SV40 and K-ras DNA, formed
small tumors, which stopped growing after reaching
about 1 cm diameter. It was estimated from the tumor
volume that the number of doublings in the nude mice
was comparable to the total doublings in culture prior
to senescence (Table 1).
The lines infected with K-ras were shown to contain
the phosphorylated form of the encoded p21 protein,
demonstrating expression ofthe viral gene. The FSVK
and Va2k cells also expressed T-antigen as shown by
immunocytofluorescence.
Thus, when normal human fibroblasts, FS-2 cells, are
infected with the Kirsten ras virus, they do not make
tumors, despite expressing the viral ras gene. In FS-2
cells expressing both T-antigen and viral K-ras protein,
i.e., FSVK cells, the tumorigenic effect ofthe viral ras
was seen as the initial growth of small tumors in the
nude mouse assay, subsequently blocked by putative
senescence gene-encoded proteins. The Va2 cells, the
positive controls, produced tumors on schedule follow-
ing infection with the K-ras virus.
These studies provide aclearexperimental dichotomy
between immortalization and tumor growth. These ex-
periments distinguish the differential effects ofthe two
processes and show that both are required for effective
tumor formation. Immortalization is shown to play a
distinctive and essential role in tumorigenesis. Con-
trariwise, senescence is showntoblocktumorformation
Table 1. Effect of KiMSV (BaEV) on immortalization and
tumor formation.
Population doublings
Cells Tumor formationa to senescence
FSK 0/9 66
FSVK-27 21b/29 60
Va2K 6/6 Previously immortalized
aNumbers are positive sites/total sites.
"Transient or excised for subculture.
in cells that have actually begun the process of tumor
formation. Identification of senescence genes and their
encoded protein products could provide an important
set of gene products to test for their potential use in
cancer therapy.
Immortalization of Normal Human
Mammary Epithelial Cells with
Human Papilloma Virus
A few years ago my laboratory began a long-term
investigation, applying molecular and cellular methods
to the identification ofgenetic changes in human breast
cancer. Initially there was no suitable medium for iso-
lating and growing primary human mammary epithelial
cells in culture. Thus, our first task was at the level of
mediadevelopment and cellculture. We have succeeded
in establishing anew mediumin which both normalcells
and tumor cells grow well, at about the same growth
rate (5).
The normal cells, derived from reduction mammo-
plasty surgery, senesce after 15 to 20 passages, rep-
resenting 40 to 50 population doublings. It was decided
to look for ways to immortalize these cells, both for
convenience in long-range experiments and to studythe
molecular genetic basis of the senescence/immortaliza-
tion switch. Among the potential methods of immor-
talization was transfection or infection with a DNA tu-
mor virus, since several of them have been implicated
in immortalization: SV40, polyoma, adenovirus, herpes
virus, Epstein-Barr virus, and human papilloma virus
(HPV) (6).
Previous studies with HPV (7) have demonstrated
the existence ofmany types; so far about 65 have been
recognized on thebasis ofdifferences in DNA sequence,
measured by cross-hybridization. Only a few of these
types have beenassociated withcarcinomas, eithergen-
ital or oral. The virus exhibits high host specificity for
squamous epithelium. No reports are known ofHPV in
glandular epithelium.
Human papilloma virus has proven very difficult to
grow in human tissues in the laboratory, but recently,
with the availability ofplasmids containingthe full viral
genome, linearized and unable to replicate autono-
mously, it has become possible to study HPV by trans-
fection. Encouraged by positive results of other inves-
tigators with keratinocytes, the known cellular hosts of
HPV (8-11), we used the same plasmids, containing
HPV 16 and HPV 18, frequently associated with cerv-
ical carcinoma, to transfect normal human mammary
epithelial cells growingin ournovel DFCI-1 (Dana-Far-
ber Cancer Institute) medium (12). This medium sup-
ports the growth of both normal and tumor-derived
mammary epithelial cells and was therefore considered
the medium of choice for selection of putative immor-
talized cells, which would have unknown growth factor
requirements.
76N cells, previously described (5), were transfected
by the calcium phosphate procedure with either HPV
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16 or 18, as well as pSVneo used for selection. Our
recovery was about i0-5 neo-resistant colonies, all of
which when tested contained the HPVplasmid. Several
individual clones as well as pools ofcolonies from single
plates of both HPV types were subsequently shown to
contain one or multiple copies ofthe HPV genome, in-
tegrated into cellular DNA, with no evidence of free
episomes.
Chromosome counts andkaryotypic analysis revealed
that some clones were hypodiploid and showed minimal
chromosome rearrangements, whereas several others
were aneuploid and rearranged, much as has been re-
ported for HPV-transfected keratinocytes (13). The hy-
podiploid clones also contained on average a single copy
of HPV per cell.
The expression ofHPV-encoded protein E7was dem-
onstrated with the use ofantibody preparations against
HPV 16/E7, a gift from D. Galloway andJ. McDougall,
and against HPV 18/E7, from L. Gissman and H. zur
Hausen. The proteins were expressed in clonally iso-
lated as well as pooled samples (12).
The changes in growth factor requirements were of
particular interest. Although the normal 76N cells used
intheseexperimentsgrowwellinDFCI-1 medium, they
do not form colonies on plastic. The cells will grow, but
at a slower rate, on D2 medium, which lacks fetal calf
serum and bovine pituitary extract. The HPV trans-
fectants grow at the same rate on both of these media
and plate with about 15% plating efficiency on each of
them. In addition, the transfectants grow and plate on
a medium, D3 + epidermal growth factor (EGF), in
which the supplemental growth factors insulin, hydro-
cortisone, triiodothyronine, and choleratoxinhave been
removed.
Finally, with respect to immortalization and tumor-
forming ability, the parental 76N cells senesce after 15
to20passages inculture, whereas allofthetested clonal
and pooled transfectants have grown 200 or more pas-
sages with no decrease in growth rate. In extensive
testing in the nude mouse assay, injecting 107 cells per
site subcutaneously into the mammary fat pad, no tu-
mors have appeared in 4 to 6 months in 50 mice, using
cells from several ofthe transfectants.
These results provide a clear and dramatic demon-
stration of the successful immortalization of human
mammary epithelial cells with either HPV 16 or 18.
Numerous questions arise. Does the mechanism of im-
mortalization involve the retinoblastoma protein to
which E7 protein has been shown to bind (14), or the
p53 protein, to which E6 binds (15)? Since these genes
seem to be involved in regulation ofthe cell cycle, i.e.,
quiescence versus cycling, one wonders whether the
same mechanisms regulate quiescence and senescence,
with senescence representing the constitutive expres-
sion of some gene(s) normally under regulation.
It should also be emphasized that chromosome
changes have been seen in all experimentally trans-
fected cell lines, as well as in HPV-associated tumors.
Are there specific, nonrandom gene changes-loss or
mutation-required for effective HPV-induced pheno-
typic changes? The hypodiploid cells recovered in these
experiments provide a unique opportunity to examine
this question. Whatever the answer, the genomic
changes associated with HPV transfection or infection
suggest that loss ofsuppressorgenes maybe arequisite
for immortalization.
At another level, our results impinge on genes in-
volved in mammary carcinoma and whether HPV or a
related DNA tumor virus may be implicated. As with
cervical carcinoma, where HPV seems to be involved
butnotasoledeterminantoftumorigenesis, might HPV
play a similar role in breast cancer? In view ofthe mul-
tiple types ofHPV and the difficulty ofidentifying new
types, this question may remain moot for some time. It
should be emphasized, however, that the changes seen
inthe transfected 76N cells require notonly the expres-
sion of HPV-encoded genes, but also their interaction
with cellular gene products. Thus, host specificity is
expressed at the level of host cell recognition of viral
gene products, and the ability of mammary epithelial
cells to show this recognition is what really suggests
that HPV might play a role in breast cancer.
I thank Stephanie Budd for preparing the manuscript. This work
was supported by Public Health Service grant CA 39814 from the
National Cancer Institute.
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